
The 11th Alzheimer's Disease Drug Discovery International Conference, held in Jersey City, NJ, USA, included topics covering new therapeutic developments in the field of Alzheimer's disease. This conference report highlights selected presentations on targeting pathological tau for the prevention or treatment of Alzheimer's disease. Investigational approaches discussed include aminothienopyridazine inhibitors of tau aggregation, the alternative splicing of tau pre-mRNA, protein phosphatase 2A as a potential therapeutic target, and immunotherapy and macroautophagy approaches for clearing aberrant tau protein from the brain.
The HDAC Inhibitors meeting, held in Boston, included topics covering new therapeutic developments in the field of HDAC inhibitors. This conference report highlights selected presentations on HDAC inhibitors for the treatment of cancer, inflammation, and neurodegenerative and other CNS diseases. Investigational drugs discussed include several compounds under evaluation by Karus Therapeutics Ltd, OCID-4681 (Orchid Research Laboratories Ltd) and EVP-0334 (EnVivo Pharmaceuticals Inc).
The Natural Peptides to Drugs congress, held in Zermatt, Switzerland, included topics covering new therapeutic developments in the field of peptide-and protein-based drugs derived from natural products. This conference report highlights selected presentations on drug discovery from natural peptides, natural peptide-based drugs in preclinical and clinical development, and peptide candidates. Investigational drugs discussed include novel small peptides from KAI Pharmaceuticals Inc, XEP-018 (Atheris Laboratories), MKC-253 (MannKind Corp), AEZS-108 (AEterna Zentaris Inc) and XG-102 (Auris Medical AG/Xigen SA).
The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Exelixis Inc and Nektar Therapeutics. Investigational drugs from Exelixis, including XL-184 (in collaboration with Bristol-Myers Squibb Co), XL-147 and XL-765 (both in collaboration with sanofi-aventis), and from Nektar, including NKTR-118 and NKTR-119 (both now licensed to AstraZeneca plc), NKTR-171, NKTR-181, NKTR-194, NKTR-102, and NKTR-105, are discussed.
SMi's fifth annual ADMET Conference, held in London, included topics covering new developments in the field of ADMET. This conference report highlights selected presentations on ADME optimization in drug discovery; targeting drugs to the brain; predicting bonds that might be attacked during metabolism; treating Caco-2 membranes with vinblastine to enhance P-glycoprotein interactions; predictive ADMET in hit-to-lead optimization; structure-based studies of ADMET targets; an accelerated process for integrated drug development; building hypotheses in lead selection and optimization; supersaturation effects; the prediction of drug-drug interactions; developing a mechanism-based pharmacokinetic/pharmacodynamic model; drug transporter assays in drug discovery; time-dependent inhibition screens in early drug discovery; the system-dependent inhibition of CYP enzymes; the integrating predictive toxicology framework OpenTox; high-content analysis for predictive cytotoxicity testing; and emerging in vitro toxicity assays.